0001209191-23-006375.txt : 20230202 0001209191-23-006375.hdr.sgml : 20230202 20230202181526 ACCESSION NUMBER: 0001209191-23-006375 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230131 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Frohlich Tom CENTRAL INDEX KEY: 0001823925 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 23582766 MAIL ADDRESS: STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC. STREET 2: 1600 FAIRVIEW AVE. E. CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-31 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001823925 Frohlich Tom C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98109 0 1 0 0 Chief Operating Officer Common Stock 2023-01-31 4 M 0 8333 A 152240 D Common Stock 2023-01-31 4 S 0 4566 24.6824 D 147674 D Restricted Stock Unirt 2023-01-31 4 M 0 8333 0.00 D Common Stock 8333 16667 D Stock Option (Right to Buy) 25.27 2023-01-31 4 A 0 84000 0.00 A 2033-01-30 Common Stock 84000 84000 D Restricted Stock Unit 2023-01-31 4 A 0 21000 0.00 A Common Stock 21000 21000 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2023-02-02